Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.18M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -5.89, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.68M shares, decreasing 20.75% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 324.76K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.